- Home
- SDHY vs RGNX Comparison
SDHY vs RGNX Comparison
Compare SDHY & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDHY
- RGNX
- Stock Information
- Founded
- SDHY 2020
- RGNX 2008
- Country
- SDHY United States
- RGNX United States
- Employees
- SDHY N/A
- RGNX N/A
- Industry
- SDHY Finance/Investors Services
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SDHY Finance
- RGNX Health Care
- Exchange
- SDHY Nasdaq
- RGNX Nasdaq
- Market Cap
- SDHY 402.7M
- RGNX 372.1M
- IPO Year
- SDHY N/A
- RGNX 2015
- Fundamental
- Price
- SDHY $16.41
- RGNX $7.37
- Analyst Decision
- SDHY
- RGNX Strong Buy
- Analyst Count
- SDHY 0
- RGNX 12
- Target Price
- SDHY N/A
- RGNX $36.00
- AVG Volume (30 Days)
- SDHY 94.0K
- RGNX 1.8M
- Earning Date
- SDHY 01-01-0001
- RGNX 02-25-2025
- Dividend Yield
- SDHY 8.46%
- RGNX N/A
- EPS Growth
- SDHY N/A
- RGNX N/A
- EPS
- SDHY 1.07
- RGNX N/A
- Revenue
- SDHY N/A
- RGNX $84,327,000.00
- Revenue This Year
- SDHY N/A
- RGNX $2.92
- Revenue Next Year
- SDHY N/A
- RGNX $234.86
- P/E Ratio
- SDHY $14.31
- RGNX N/A
- Revenue Growth
- SDHY N/A
- RGNX N/A
- 52 Week Low
- SDHY $13.93
- RGNX $6.56
- 52 Week High
- SDHY $15.50
- RGNX $28.80
- Technical
- Relative Strength Index (RSI)
- SDHY 56.32
- RGNX 42.98
- Support Level
- SDHY $16.06
- RGNX $6.98
- Resistance Level
- SDHY $16.28
- RGNX $7.70
- Average True Range (ATR)
- SDHY 0.11
- RGNX 0.57
- MACD
- SDHY 0.03
- RGNX 0.02
- Stochastic Oscillator
- SDHY 90.12
- RGNX 35.53
About SDHY PGIM Short Duration High Yield Opportunities Fund
PGIM Short Duration High Yield Opportunities is a closed-end management investment company. The fund's investment objective is to provide total return, through a combination of current income and capital appreciation. Its seeks to achieve its objective by investing in a diversified portfolio of high yield fixed income instruments.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.